(Q33571416)

28 July 2017

title

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology (English)

1 reference

28 July 2017

0 references

2

Heinrich P Mattle

1 reference

28 July 2017

Christian P Kamm

1

1 reference

28 July 2017

SWABIMS Study Group

series ordinal

3

1 reference

28 July 2017

publication date

14 December 2009

1 reference

28 July 2017

1 reference

28 July 2017

volume

10

1 reference

28 July 2017

page(s)

115

1 reference

Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Statin therapy inhibits remyelination in the central nervous system.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Cross-validation of brain segmentation by SPM5 and SIENAX.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

The immunopathology of multiple sclerosis: an overview

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2801665

Effect of pravastatin on outcomes after cardiac transplantation.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-10-115

Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-10-115

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-10-115

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-10-115

Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1745-6215-10-115

WHO Expert Committee on Biological Standardization. Thirty-fifth report

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20003436

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20003436

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20003436

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1745-6215-10-115

1 reference

Dimensions Publication ID

28 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1745-6215-10-115

9 September 2019

1 reference

28 July 2017

1 reference